摘要
目的研究恩替卡韦辅助治疗乙肝肝硬化失代偿期的临床效果。方法随机选取2012年4月—2014年4月该院收治的70例乙型肝炎肝硬化失代偿期患者为研究对象,将其随机分为观察组和对照组,对照组采用常规对症治疗,观察组在常规治疗基础上,采用恩替卡韦辅助治疗,比较两组患者治疗效果。结果观察组HBV-DNA转阴率明显高于对照组,且死亡率比对照组低,差异有统计学意义(χ2=8.548,P<0.05)。结论恩替卡韦辅助治疗乙型肝炎引起的肝硬化失代偿期患者,能有效降低肝硬化失代偿期死亡率,疗效显著,具有临床推广价值。
Objective To study the clinical effect of entecavir treatment of hepatitis B decompensated liver cirrhosis.Methods Atotal of 2012 from April 2014 4 months in our hospital from 58 cases of hepatitis B cirrhosis decompensated patients as the research object, randomly divided into observation group and control group, control group was treated with conventional symptomatic treatment, observation group in the conventional treatment on the basis of using en entecavir adjuvant therapy, compared two groups of patients with therapeutic effect. Results Observation group HBV-DNA negative rate was significantly higher than that of the control group, the difference is statistically significant(χ2=8.548, P<0.05). Conclusion EN entecavir adjuvant therapy for hepatitis B caused by cirrhosis decompensated patients, can effectively reduce the cirrhosis decompensation stage mortality and significant effect, with clinical value.
出处
《中外医疗》
2015年第29期131-133,共3页
China & Foreign Medical Treatment
